JP6373490B2 - Ｔｏｌｌ様受容体モジュレーターを調製する方法 - Google Patents

Ｔｏｌｌ様受容体モジュレーターを調製する方法 Download PDF

Info

Publication number
JP6373490B2
JP6373490B2 JP2017514494A JP2017514494A JP6373490B2 JP 6373490 B2 JP6373490 B2 JP 6373490B2 JP 2017514494 A JP2017514494 A JP 2017514494A JP 2017514494 A JP2017514494 A JP 2017514494A JP 6373490 B2 JP6373490 B2 JP 6373490B2
Authority
JP
Japan
Prior art keywords
formula
compound
substituted
group
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017514494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526729A (ja
Inventor
ダリン アレン，
ダリン アレン，
ブランドン ヒース ブラウン，
ブランドン ヒース ブラウン，
ジェシカ ジェード チャオ，
ジェシカ ジェード チャオ，
ランダル エル． ハルコン，
ランダル エル． ハルコン，
ポール ハルヴァティン，
ポール ハルヴァティン，
ライアン マクファデン，
ライアン マクファデン，
ポール ロエスル，
ポール ロエスル，
エルウィナ ルディオ，
エルウィナ ルディオ，
ホン ヤン，
ホン ヤン，
リチャード ハン チュー ユ，
リチャード ハン チュー ユ，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド, ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2017526729A publication Critical patent/JP2017526729A/ja
Application granted granted Critical
Publication of JP6373490B2 publication Critical patent/JP6373490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
JP2017514494A 2014-09-16 2015-09-14 Ｔｏｌｌ様受容体モジュレーターを調製する方法 Active JP6373490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051044P 2014-09-16 2014-09-16
US62/051,044 2014-09-16
PCT/US2015/050039 WO2016044183A1 (en) 2014-09-16 2015-09-14 Methods of preparing toll-like receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018134200A Division JP6596127B2 (ja) 2014-09-16 2018-07-17 Ｔｏｌｌ様受容体モジュレーターを調製する方法

Publications (2)

Publication Number Publication Date
JP2017526729A JP2017526729A (ja) 2017-09-14
JP6373490B2 true JP6373490B2 (ja) 2018-08-15

Family

ID=54291584

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017514494A Active JP6373490B2 (ja) 2014-09-16 2015-09-14 Ｔｏｌｌ様受容体モジュレーターを調製する方法
JP2018134200A Active JP6596127B2 (ja) 2014-09-16 2018-07-17 Ｔｏｌｌ様受容体モジュレーターを調製する方法
JP2019176572A Active JP7063865B2 (ja) 2014-09-16 2019-09-27 Ｔｏｌｌ様受容体モジュレーターを調製する方法
JP2022016438A Active JP7333843B2 (ja) 2014-09-16 2022-02-04 Ｔｏｌｌ様受容体モジュレーターを調製する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018134200A Active JP6596127B2 (ja) 2014-09-16 2018-07-17 Ｔｏｌｌ様受容体モジュレーターを調製する方法
JP2019176572A Active JP7063865B2 (ja) 2014-09-16 2019-09-27 Ｔｏｌｌ様受容体モジュレーターを調製する方法
JP2022016438A Active JP7333843B2 (ja) 2014-09-16 2022-02-04 Ｔｏｌｌ様受容体モジュレーターを調製する方法

Country Status (20)

Country Link
US (1) US9573952B2 (https=)
EP (3) EP3461828B1 (https=)
JP (4) JP6373490B2 (https=)
KR (3) KR102306860B1 (https=)
CN (2) CN115043840A (https=)
AR (1) AR101882A1 (https=)
AU (2) AU2015318062B2 (https=)
BR (1) BR112017005100A2 (https=)
CA (1) CA2960384C (https=)
EA (1) EA201790373A1 (https=)
ES (3) ES2845205T3 (https=)
IL (1) IL250849A0 (https=)
MX (1) MX2017003288A (https=)
NZ (1) NZ729526A (https=)
PL (2) PL3848375T3 (https=)
PT (2) PT3194402T (https=)
SG (1) SG11201701472VA (https=)
SI (1) SI3461828T1 (https=)
TW (2) TWI780423B (https=)
WO (1) WO2016044183A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
TW201915000A (zh) * 2017-09-22 2019-04-16 大陸商江蘇恆瑞醫藥股份有限公司 稠合雜芳基衍生物、其製備方法及其在醫藥上的應用
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
CA3249821A1 (en) * 2022-04-26 2023-11-02 Bigelow Laboratory For Ocean Sciences PRODUCTION PROCESSES FOR HALOGENATED COMPOUNDS

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JP2886570B2 (ja) 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
JPH05320143A (ja) * 1992-03-18 1993-12-03 Mochida Pharmaceut Co Ltd 新規ピリミジン誘導体
TW274550B (https=) 1992-09-26 1996-04-21 Hoechst Ag
EP0743855A1 (en) 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
BR9710808A (pt) 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
WO2000000478A1 (en) 1998-06-26 2000-01-06 Bristol-Myers Squibb Pharma Company Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US7169778B2 (en) 1999-09-15 2007-01-30 Warner-Lambert Company Pteridinones as kinase inhibitors
US6452325B1 (en) 2000-07-24 2002-09-17 Thermoplastic Processes, Inc. Shatterproofing of fluorescent lamps
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
UA76512C2 (en) 2001-09-04 2006-08-15 Boehringer Ingelheim Pharma Dihydropteridinones, a method for producing thereof and use thereof as medicament
JP3876265B2 (ja) 2003-02-26 2007-01-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ジヒドロプテリジノン、その製造方法及び薬物形態での使用
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CA2617589A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
EP2657235A1 (en) * 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2007103554A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
EP2004193A2 (en) 2006-03-13 2008-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2009541284A (ja) 2006-06-23 2009-11-26 アストラゼネカ・アクチエボラーグ プテリジン誘導体およびカテプシン阻害剤としてのそれらの使用
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
AR065372A1 (es) 2007-02-19 2009-06-03 Smithkline Beecham Corp Derivados de purina
AU2008228303B2 (en) 2007-03-22 2012-04-19 Takeda Pharmaceutical Company Limited Substituted pyrimidodiazepines useful as PLK1 inhibitors
KR20120003499A (ko) * 2007-04-05 2012-01-10 지멘스 메디컬 솔루션즈 유에스에이, 인크. 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조
US20100179109A1 (en) * 2007-04-05 2010-07-15 Baldwin Jonh J Renin inhibitors
ES2441196T3 (es) * 2007-04-18 2014-02-03 Kissei Pharmaceutical Co., Ltd. Derivado de anillo condensado nitrogenado, composiciones farmacéuticas que lo contienen, y su uso con fines médicos
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
WO2009022185A2 (en) 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
US20090291938A1 (en) 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN101284810A (zh) * 2008-06-02 2008-10-15 秦引林 氰基吡咯烷和氰基噻唑烷衍生物
RS53347B (sr) * 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
CA2772253C (en) * 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
US20130273005A1 (en) * 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv

Also Published As

Publication number Publication date
TWI692468B (zh) 2020-05-01
AR101882A1 (es) 2017-01-18
SI3461828T1 (sl) 2021-01-29
EP3194402B1 (en) 2018-11-21
KR20210118985A (ko) 2021-10-01
KR101978809B1 (ko) 2019-05-15
US20160075707A1 (en) 2016-03-17
ES2845205T3 (es) 2021-07-26
TWI780423B (zh) 2022-10-11
US9573952B2 (en) 2017-02-21
SG11201701472VA (en) 2017-04-27
JP2019214626A (ja) 2019-12-19
PT3461828T (pt) 2021-01-26
AU2015318062A1 (en) 2017-03-16
AU2018236824B2 (en) 2020-04-23
CN107074860A (zh) 2017-08-18
AU2015318062B2 (en) 2018-07-05
KR102306860B1 (ko) 2021-09-30
EA201790373A1 (ru) 2017-08-31
JP6596127B2 (ja) 2019-10-23
CA2960384C (en) 2019-07-23
JP7333843B2 (ja) 2023-08-25
ES2975520T3 (es) 2024-07-08
JP7063865B2 (ja) 2022-05-09
ES2706527T3 (es) 2019-03-29
PL3848375T3 (pl) 2024-05-06
EP3848375B1 (en) 2023-12-27
NZ729526A (en) 2018-05-25
MX2017003288A (es) 2017-06-28
CN107074860B (zh) 2022-07-15
KR20170048592A (ko) 2017-05-08
EP3848375C0 (en) 2023-12-27
JP2022051834A (ja) 2022-04-01
KR102457426B1 (ko) 2022-10-24
EP3461828B1 (en) 2020-11-25
EP3194402A1 (en) 2017-07-26
WO2016044183A1 (en) 2016-03-24
CN115043840A (zh) 2022-09-13
PT3194402T (pt) 2019-02-11
EP3461828A2 (en) 2019-04-03
TW201625524A (zh) 2016-07-16
TW202043195A (zh) 2020-12-01
KR20190053292A (ko) 2019-05-17
EP3461828A3 (en) 2019-05-01
IL250849A0 (en) 2017-04-30
JP2017526729A (ja) 2017-09-14
JP2018158953A (ja) 2018-10-11
BR112017005100A2 (pt) 2017-12-05
AU2018236824A1 (en) 2018-10-18
EP3848375A1 (en) 2021-07-14
PL3461828T3 (pl) 2021-07-19
CA2960384A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
JP6596127B2 (ja) Ｔｏｌｌ様受容体モジュレーターを調製する方法
WO2018095426A1 (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
JP4469174B2 (ja) インポテンス治療用の新規化合物
HK40051817A (en) Methods of preparing intermediates for toll-like receptor modulators
HK40051817B (en) Methods of preparing intermediates for toll-like receptor modulators
HK40005950A (en) Methods of preparing toll-like receptor modulators
HK40005950B (en) Methods of preparing toll-like receptor modulators
HK1239684A1 (en) Methods of preparing toll-like receptor modulators
HK1239684B (en) Methods of preparing toll-like receptor modulators
HK1239677A1 (en) Methods of preparing toll-like receptor modulators
HK1239677B (en) Methods of preparing toll-like receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180604

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180717

R150 Certificate of patent or registration of utility model

Ref document number: 6373490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250